Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DALBA-study
2025-522088-13-00Phase 4Authorised
- Sponsor
- Central Denmark Region
- Start
- Oct 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of dalbavancin in periprosthetic joint infection (PJI) (3 arms), sponsored by Central Denmark Region. Primary endpoint: Cost-utility during acute antibiotic treatment. Planned start Oct 2025; status: authorised.
02
Drugs
dalbavancin
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on 2025-522088-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522088-13-00.